Physician profile
James E Lambeth
NPI 1205888419
$12,458.88
in general payments reported to CMS, 2019-2025
47 companies · $1,623 in 2025
The $1,623 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,569 · 2020: $661 · 2021: $650 · 2022: $2,136 · 2023: $2,475 · 2024: $2,346 · 2025: $1,623.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,432 · Education: $10.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,432.47 |
| Education | $10.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $2,273.02 | 2019-2025 | Biktarvy |
| Viiv Healthcare Company | $1,315.65 | 2019-2025 | Rukobia, Apretude, Cabenuva |
| Novo Nordisk INC | $1,199.48 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $1,010.06 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $763.65 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Merck Sharp & Dohme LLC | $756.87 | 2019-2025 | Pifeltro, Delstrigo, Gardasil |
| Lilly USA, LLC | $745.69 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $628.70 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $565.89 | 2019-2025 | Trintellix |
| Pfizer INC. | $544.28 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $386.15 | 2019-2025 | Jardiance |
| Emd Serono, INC. | $292.22 | 2019-2025 | Serostim |
| Amgen INC. | $187.87 | 2019-2025 | Repatha, Otezla, Repatha |
| Janssen Biotech, INC. | $187.20 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $150.43 | 2022-2023 | Quviviq |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Lambeth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.